Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Darko Barisic, Christopher R Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E Carson, Santo Raggiri, Sonia Debek, Benedikt Pelzer, Ceyda Durmaz, Qing Deng, Priya Lakra, Martin Rivas, Christian Steidl, David W Scott, Andrew P Weng, Christopher E Mason, Michael R Green, Ari Melnick
No abstract text is available yet for this article.
April 8, 2024: Cancer Cell
#2
Leandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, Katerina Hatzi, Karen L Bunting, Lucas A Tsikitas, Alka Mallik, Ana I Robles, Jennifer Walling, Lyuba Varticovski, Rita Shaknovich, Kapil N Bhalla, Gabriela Chiosis, Ari Melnick
No abstract text is available yet for this article.
April 3, 2024: Nature Medicine
#3
JOURNAL ARTICLE
Jie Li, Christopher R Chin, Hsia-Yuan Ying, Cem Meydan, Matthew R Teater, Min Xia, Pedro Farinha, Katsuyoshi Takata, Chi-Shuen Chu, Yiyue Jiang, Jenna Eagles, Verena Passerini, Zhanyun Tang, Martin A Rivas, Oliver Weigert, Trevor J Pugh, Amy Chadburn, Christian Steidl, David W Scott, Robert G Roeder, Christopher E Mason, Roberta Zappasodi, Wendy Béguelin, Ari M Melnick
Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d induces a more severe mouse lymphoma phenotype (vs either allele alone) and unexpectedly confers an immune evasive microenvironment manifesting as CD8+ T-cell exhaustion and reduced infiltration. This is linked to profound repression of immune synapse genes that mediate crosstalk with T-cells, resulting in aberrant GC B cell fate decisions...
April 3, 2024: Nature Communications
#4
JOURNAL ARTICLE
Qing Deng, Priya Lakra, Panhong Gou, Haopeng Yang, Cem Meydan, Matthew Teater, Christopher Chin, Wenchao Zhang, Tommy Dinh, Usama Hussein, Xubin Li, Estela Rojas, Weiguang Liu, Patrick K Reville, Atish Kizhakeyil, Darko Barisic, Sydney Parsons, Ashley Wilson, Jared Henderson, Brooks Scull, Channabasavaiah Gurumurthy, Francisco Vega, Amy Chadburn, Branko Cuglievan, Nader Kim El-Mallawany, Carl Allen, Christopher Mason, Ari Melnick, Michael R Green
SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. Furthermore, monoallelic Smarca4 deletion drove GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone...
March 1, 2024: Cancer Cell
#5
JOURNAL ARTICLE
Darko Barisic, Christopher R Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E Carson, Santo Raggiri, Sonia Debek, Benedikt Pelzer, Ceyda Durmaz, Qing Deng, Priya Lakra, Martin Rivas, Christian Steidl, David W Scott, Andrew P Weng, Christopher E Mason, Michael R Green, Ari Melnick
ARID1A, a subunit of the canonical BAF nucleosome remodeling complex, is commonly mutated in lymphomas. We show that ARID1A orchestrates B cell fate during the germinal center (GC) response, facilitating cooperative and sequential binding of PU.1 and NF-kB at crucial genes for cytokine and CD40 signaling. The absence of ARID1A tilts GC cell fate toward immature IgM+ CD80- PD-L2- memory B cells, known for their potential to re-enter new GCs. When combined with BCL2 oncogene, ARID1A haploinsufficiency hastens the progression of aggressive follicular lymphomas (FLs) in mice...
March 7, 2024: Cancer Cell
#6
JOURNAL ARTICLE
Yaseswini Neelamraju, Evisa Gjini, Sagar Chhangawala, Hao Fan, Shuning He, Chang-Bin Jing, Ashley T Nguyen, Subhash Prajapati, Caroline Sheridan, Yariv Houvras, Ari Melnick, A Thomas Look, Francine E Garrett-Bakelman
INTRODUCTION: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and dysplasia. The gene encoding ten-eleven translocation 2 ( tet 2), a dioxygenase enzyme that catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, is a recurrently mutated tumor suppressor gene in MDS and other myeloid malignancies. Previously, we reported a stable zebrafish line with a loss-of-function mutation in the tet2 gene...
2023: Front Hematol
#7
JOURNAL ARTICLE
Firas M Safa, Terri Rasmussen, Lorena Fontan, Min Xia, Ari Melnick, Adrian Wiestner, Patricia Lobelle-Rich, Jan A Burger, Yara Mouawad, Hana Safah, Erik K Flemington, Nakhle S Saba
B cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-κB activation. Inhibition of MALT1 in preclinical models has proven efficacious in many B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma. We sought to examine the role of MALT1 in B-ALL and determine the biological consequences of its inhibition...
September 28, 2023: Haematologica
#8
Vianne R Gao, Rui Yang, Arnav Das, Renhe Luo, Hanzhi Luo, Dylan R McNally, Ioannis Karagiannidis, Martin A Rivas, Zhong-Min Wang, Darko Barisic, Alireza Karbalayghareh, Wilfred Wong, Yingqian A Zhan, Christopher R Chin, William Noble, Jeff A Bilmes, Effie Apostolou, Michael G Kharas, Wendy Béguelin, Aaron D Viny, Danwei Huangfu, Alexander Y Rudensky, Ari M Melnick, Christina S Leslie
The identification of cell-type-specific 3D chromatin interactions between regulatory elements can help to decipher gene regulation and to interpret the function of disease-associated non-coding variants. However, current chromosome conformation capture (3C) technologies are unable to resolve interactions at this resolution when only small numbers of cells are available as input. We therefore present ChromaFold, a deep learning model that predicts 3D contact maps and regulatory interactions from single-cell ATAC sequencing (scATAC-seq) data alone...
July 28, 2023: bioRxiv
#9
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan, Alexis Thurmond, Ling Wang, Martin Carroll, Larry D Cripe, Hugo Fernandez, Christopher E Mason, Elisabeth Paietta, Gail J Roboz, Zhuoxin Sun, Martin S Tallman, Yanming Zhang, Mithat Gönen, Ross Levine, Ari M Melnick, Maria Kleppe, Francine E Garrett-Bakelman
No abstract text is available yet for this article.
July 6, 2023: Blood Cancer Journal
#10
JOURNAL ARTICLE
Cristiana O'Brien, Tianyi Ling, Jacob M Berman, Rachel Culp-Hill, Julie A Reisz, Vincent Rondeau, Soheil Jahangiri, Jonathan St-Germain, Vinitha Macwan, Audrey Astori, Andy Zeng, Jun Young Hong, Meng Li, Min Yang, Sadhan Jana, Fabia Gamboni, Emily Tsao, Weiyi Liu, John E Dick, Hening Lin, Ari Melnick, Anastasia Tikhonova, Andrea Arruda, Mark D Minden, Brian Raught, Angelo D'Alessandro, Courtney L Jones
Outcomes for patients with acute myeloid leukemia (AML) remain poor due to the inability of current therapeutic regimens to fully eradicate disease-initiating leukemia stem cells (LSC). Previous studies have demonstrated that oxidative phosphorylation (OXPHOS) is an essential process that is targetable in LSC. Sirtuin 3 (SIRT3), a mitochondrial deacetylase with a multi-faceted role in metabolic regulation, has been shown to regulate OXPHOS in cancer models; however, it has not yet been studied in the context of LSC...
September 1, 2023: Haematologica
#11
JOURNAL ARTICLE
Shivem B Shah, Christopher R Carlson, Kristine Lai, Zhe Zhong, Grazia Marsico, Katherine M Lee, Nicole E Félix Vélez, Elisabeth B Abeles, Mayar Allam, Thomas Hu, Lauren D Walter, Karen E Martin, Khanjan Gandhi, Scott D Butler, Rishi Puri, Angela L McCleary-Wheeler, Wayne Tam, Olivier Elemento, Katsuyoshi Takata, Christian Steidl, David W Scott, Lorena Fontan, Hideki Ueno, Benjamin D Cosgrove, Giorgio Inghirami, Andrés J García, Ahmet F Coskun, Jean L Koff, Ari Melnick, Ankur Singh
Activated B-cell-like diffuse large B-cell lymphomas (ABC-DLBCLs) are characterized by constitutive activation of nuclear factor κB driven by the B-cell receptor (BCR) and Toll-like receptor (TLR) pathways. However, BCR-pathway-targeted therapies have limited impact on DLBCLs. Here we used >1,100 DLBCL patient samples to determine immune and extracellular matrix cues in the lymphoid tumour microenvironment (Ly-TME) and built representative synthetic-hydrogel-based B-cell-lymphoma organoids accordingly...
April 2023: Nature Materials
#12
Jie Li, Christopher R Chin, Hsia-Yuan Ying, Cem Meydan, Matthew R Teater, Min Xia, Pedro Farinha, Katsuyoshi Takata, Chi-Shuen Chu, Martin A Rivas, Amy Chadburn, Christian Steidl, David W Scott, Robert G Roeder, Christopher E Mason, Wendy Béguelin, Ari M Melnick
UNLABELLED: Mutations affecting enhancer chromatin regulators CREBBP and KMT2D are highly co-occurrent in germinal center (GC)-derived lymphomas and other tumors, even though regulating similar pathways. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d (C+K) indeed accelerated lymphomagenesis. C+K haploinsufficiency induced GC hyperplasia by altering cell fate decisions, skewing B cells away from memory and plasma cell differentiation. C+K deficiency particularly impaired enhancer activation for immune synapse genes involved in exiting the GC reaction...
February 13, 2023: bioRxiv
#13
MULTICENTER STUDY
Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, Lubomir Sokol, Zhengming Chen, Nikita Kotlov, Grigorii Nos, Maria Sorokina, Vladislav Maksimov, Andrea Sboner, Michael Sigouros, Koen van Besien, Steven Horwitz, Sarah C Rutherford, Erin Mulvey, Maria V Revuelta, Jenny Xiang, Alicia Alonso, Ari Melnick, Olivier Elemento, Giorgio Inghirami, John P Leonard, Leandro Cerchietti, Peter Martin
Peripheral T-cell lymphomas (PTCL) with T-follicular helper phenotype (PTCL-TFH) has recurrent mutations affecting epigenetic regulators, which may contribute to aberrant DNA methylation and chemoresistance. This phase 2 study evaluated oral azacitidine (CC-486) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as initial treatment for PTCL. CC-486 at 300 mg daily was administered for 7 days before C1 of CHOP, and for 14 days before CHOP C2-6. The primary end point was end-of-treatment complete response (CR)...
May 4, 2023: Blood
#14
JOURNAL ARTICLE
Julie Leca, Franҫois Lemonnier, Cem Meydan, Jonathan Foox, Samah El Ghamrasni, Diana-Laure Mboumba, Gordon S Duncan, Jerome Fortin, Takashi Sakamoto, Chantal Tobin, Kelsey Hodgson, Jillian Haight, Logan K Smith, Andrew J Elia, Daniel Butler, Thorsten Berger, Laurence de Leval, Christopher E Mason, Ari Melnick, Philippe Gaulard, Tak W Mak
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follicular helper (Tfh) cells and exhibits a prominent tumor microenvironment (TME). IDH2 and TET2 mutations co-occur frequently in AITL, but their contribution to tumorigenesis is poorly understood. We developed an AITL mouse model that is driven by Idh2 and Tet2 mutations. Malignant Tfh cells display aberrant transcriptomic and epigenetic programs that impair TCR signaling. Neoplastic Tfh cells bearing combined Idh2 and Tet2 mutations show altered cross-talk with germinal center B cells that promotes B cell clonal expansion while decreasing Fas-FasL interaction and reducing B cell apoptosis...
February 13, 2023: Cancer Cell
#15
JOURNAL ARTICLE
Coraline Mlynarczyk, Matt Teater, Juhee Pae, Christopher R Chin, Ling Wang, Theinmozhi Arulraj, Darko Barisic, Antonin Papin, Kenneth B Hoehn, Ekaterina Kots, Jonatan Ersching, Arnab Bandyopadhyay, Ersilia Barin, Hui Xian Poh, Chiara M Evans, Amy Chadburn, Zhengming Chen, Hao Shen, Hannah M Isles, Benedikt Pelzer, Ioanna Tsialta, Ashley S Doane, Huimin Geng, Muhammad Hassan Rehman, Jonah Melnick, Wyatt Morgan, Diu T T Nguyen, Olivier Elemento, Michael G Kharas, Samie R Jaffrey, David W Scott, George Khelashvili, Michael Meyer-Hermann, Gabriel D Victora, Ari Melnick
Multicellular life requires altruistic cooperation between cells. The adaptive immune system is a notable exception, wherein germinal center B cells compete vigorously for limiting positive selection signals. Studying primary human lymphomas and developing new mouse models, we found that mutations affecting BTG1 disrupt a critical immune gatekeeper mechanism that strictly limits B cell fitness during antibody affinity maturation. This mechanism converted germinal center B cells into supercompetitors that rapidly outstrip their normal counterparts...
January 20, 2023: Science
#16
JOURNAL ARTICLE
Jerome Fortin, Ming-Feng Chiang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Julie Leca, François Lemonnier, Wanda Y Li, Miki S Gams, Takashi Sakamoto, Mandy Chu, Chantal Tobin, Eric Laugesen, Troy M Robinson, Annick You-Ten, Daniel J Butler, Thorsten Berger, Mark D Minden, Ross L Levine, Cynthia J Guidos, Ari M Melnick, Christopher E Mason, Tak W Mak
Mutations in IDH1, IDH2 , and TET2 are recurrently observed in myeloid neoplasms. IDH1 and IDH2 encode isocitrate dehydrogenase isoforms, which normally catalyze the conversion of isocitrate to α-ketoglutarate (α-KG). Oncogenic IDH1/2 mutations confer neomorphic activity, leading to the production of D-2-hydroxyglutarate (D-2-HG), a potent inhibitor of α-KG-dependent enzymes which include the TET methylcytosine dioxygenases. Given their mutual exclusivity in myeloid neoplasms, IDH1 , IDH2 , and TET2 mutations may converge on a common oncogenic mechanism...
January 24, 2023: Proceedings of the National Academy of Sciences of the United States of America
#17
EDITORIAL
Ruth Flümann, Julia Hansen, Benedikt W Pelzer, Pascal Nieper, Tim Lohmann, Ilmars Kisis, Tobias Riet, Viktoria Kohlhas, Phuong-Hien Nguyen, Martin Peifer, Nima Abedpour, Graziella Bosco, Roman K Thomas, Moritz Kochanek, Jacqueline Knüfer, Lorenz Jonigkeit, Filippo Beleggia, Alessandra Holzem, Reinhard Büttner, Philipp Lohneis, Jörn Meinel, Monika Ortmann, Thorsten Persigehl, Michael Hallek, Dinis Pedro Calado, Markus Chmielewski, Sebastian Klein, Joachim R Göthert, Bjoern Chapuy, Branko Zevnik, F Thomas Wunderlich, Bastian von Tresckow, Ron D Jachimowicz, Ari M Melnick, Hans Christian Reinhardt, Gero Knittel
UNLABELLED: Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B cell-specific Prdm1 or Spib aberrations on the background of oncogenic Myd88 and Bcl2 lesions. We deployed whole-exome sequencing, transcriptome, flow-cytometry, and mass cytometry analyses to demonstrate that Prdm1- or Spib-altered lymphomas display molecular features consistent with prememory B cells and light-zone B cells, whereas lymphomas lacking these alterations were enriched for late light-zone and plasmablast-associated gene sets...
January 6, 2023: Blood cancer discovery
#18
EDITORIAL
Leandro Venturutti, Martin A Rivas, Benedikt W Pelzer, Ruth Flümann, Julia Hansen, Ioannis Karagiannidis, Min Xia, Dylan R McNally, Yusuke Isshiki, Andrew Lytle, Matt Teater, Christopher R Chin, Cem Meydan, Gero Knittel, Edd Ricker, Christopher E Mason, Xiaofei Ye, Qiang Pan-Hammarström, Christian Steidl, David W Scott, Hans Christian Reinhardt, Alessandra B Pernis, Wendy Béguelin, Ari M Melnick
UNLABELLED: A third of patients with diffuse large B-cell lymphoma (DLBCL) present with extranodal dissemination, which is associated with inferior clinical outcomes. MYD88L265P is a hallmark extranodal DLBCL mutation that supports lymphoma proliferation. Yet extranodal lymphomagenesis and the role of MYD88L265P in transformation remain mostly unknown. Here, we show that B cells expressing Myd88L252P (MYD88L265P murine equivalent) activate, proliferate, and differentiate with minimal T-cell costimulation...
January 9, 2023: Cancer Discovery
#19
JOURNAL ARTICLE
Tatiana Erazo, Chiara M Evans, Daniel Zakheim, Karen L Chu, Alice Yunsi Refermat, Zahra Asgari, Xuejing Yang, Mariana Da Silva Ferreira, Sanjoy Mehta, Marco Vincenzo Russo, Andrea Knezevic, Xi-Ping Zhang, Zhengming Chen, Myles Fennell, Ralph Garippa, Venkatraman Seshan, Elisa de Stanchina, Olena Barbash, Connie Lee Batlevi, Christina S Leslie, Ari M Melnick, Anas Younes, Michael G Kharas
To identify drivers of sensitivity and resistance to Protein Arginine Methyltransferase 5 (PRMT5) inhibition, we perform a genome-wide CRISPR/Cas9 screen. We identify TP53 and RNA-binding protein MUSASHI2 (MSI2) as the top-ranked sensitizer and driver of resistance to specific PRMT5i, GSK-591, respectively. TP53 deletion and TP53R248W mutation are biomarkers of resistance to GSK-591. PRMT5 expression correlates with MSI2 expression in lymphoma patients. MSI2 depletion and pharmacological inhibition using Ro 08-2750 (Ro) both synergize with GSK-591 to reduce cell growth...
September 27, 2022: Nature Communications
#20
JOURNAL ARTICLE
Laurence de Leval, Ash A Alizadeh, P Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M Horwitz, Ari M Melnick, William G Morice, Ryan D Morin, Bertrand Nadel, Stefano A Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P Treon, Andrew D Zelenetz, Ranjana H Advani, Carl E Allen, Stephen M Ansell, Wing C Chan, James R Cook, Lucy B Cook, Francesco d'Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G Gribben, Olivier Hermine, Daniel J Hodson, Eric D Hsi, Giorgio Inghirami, Elaine S Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L King, Young H Ko, Ann S LaCasce, Georg Lenz, José I Martin-Subero, Miguel A Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J Rodig, Andreas Rosenwald, Gilles A Salles, Jesus San-Miguel, Kerry J Savage, Laurie H Sehn, Gianpietro Semenzato, Louis M Staudt, Steven H Swerdlow, Constantine S Tam, Judith Trotman, Julie M Vose, Oliver Weigert, Wyndham H Wilson, Jane N Winter, Catherine J Wu, Pier L Zinzani, Emanuele Zucca, Adam Bagg, David W Scott
With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level...
November 24, 2022: Blood
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
